ArticleThe Journal of clinical investigation2006
C5a and Fcgamma receptors: a mutual admiration society.
Article in The Journal of clinical investigation, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 27 citations in OpenAlex.
- The complement receptor C5aR2 regulates neutrophil activation and function contributing to neutrophil-driven epidermolysis bullosa acquisita.Frontiers in immunology · 2023Article
- Targeting of G-protein coupled receptors in sepsis.Pharmacology & therapeutics · 2020Review
- Characteristics of spinal microglia in aged and obese mice: potential contributions to impaired sensory behavior.Immunity & ageing : I & A · 2015Article
- Septicaemia models using Streptococcus pneumoniae and Listeria monocytogenes: understanding the role of complement properdin.Medical microbiology and immunology · 2014Article
- Molecular basis for downregulation of C5a-mediated inflammation by IgG1 immune complexes in allergy and asthma.Current allergy and asthma reports · 2013Review
- Mast cell anaphylatoxin receptor expression can enhance IgE-dependent skin inflammation in mice.The Journal of allergy and clinical immunology · 2013Article
- TRAF1-C5 affects quality of life in patients with primary biliary cirrhosis.Clinical & developmental immunology · 2013Article
- Novel adenovirus vectors 'capsid-displaying' a human complement inhibitor.Journal of innate immunity · 2010Article
- C5a is not involved in experimental autoimmune myasthenia gravis pathogenesis.Journal of neuroimmunology · 2008Article
- Article
Corrections and comments
- Comment on
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Phagocytosis is a key process in protection of the host against pathogens and in provision of antigens for the immune response. Synergism between C3b and IgG and their receptors in promoting adherence to and then ingestion of an antigen has been recognized for decades. Only more recently, however, has cross-talk between another complement activation fragment, the anaphylatoxin C5a, and Fcgamma receptors (FcgammaRs) been defined. In this issue of the JCI, C5a is shown to signal, via its receptor, the upregulation of activating (proinflammatory-type) FcgammaRs. Moreover, engagement of FcgammaRs by the IgG-bearing immune complex instructs the cell to synthesize more C5, from which C5a is derived. Thus, this work establishes a feedback loop whereby FcgammaR expression and function are enhanced, a very desirable event in concert with an infection but potentially deleterious in autoimmunity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.